

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

Epigenetic Characterisation of the O6 Methyl-Guanine DNA-Methyltransferase Promoter in New Zealand Melanoma Cell Lines

A thesis presented to Massey University in partial fulfillment of the requirements for the degree of

Master of Science
in
Biochemistry

at Massey University, Palmerston North,
New Zealand

William Ernest Rutherford

2010

Abstract

New Zealand has the second highest incidence of melanoma skin cancer in the world. Chemotherapy is the standard treatment for melanoma derived tumours which have undergone metastasis and current therapies have limited benefit. There is a great need for new therapies and to increase the efficacy of current therapies.

Temozolomide (TMZ) is a chemotherapy agent effective in the treatment of both metastatic melanoma and glioblastoma (brain cancer), although TMZ resistance has been observed in many tumours. The activity of the DNA repair enzyme O⁶ methyl-guanine methyltransferase (MGMT) is thought to be largely responsible for TMZ resistance.

MGMT protects the cell from the effects of TMZ by removing cytotoxic lesions placed on the DNA. Mechanisms of regulation of MGMT expression remain unclear in melanoma. DNA methylation at the MGMT promoter has been linked to MGMT silencing in some cancers and has been associated with specific chromatin modifications. The present study was aimed at investigating the promoter methylation status of MGMT in primary melanoma cell lines using a new technique named methyl DNA immuno-precipitation (MeDIP). Next, the chromatin immuno-precipitation (ChIP) method was used to examine post translational modifications on the surrounding chromatin. The data obtained was correlated with both MGMT transcription levels and TMZ sensitivity.

The promoter methylation status of MGMT has been used to predict the clinical responsiveness of glioblastoma patients to TMZ. Establishing the regulatory mechanisms of MGMT expression in melanoma patients would validate a means to predict clinical responsiveness to TMZ. Furthermore, establishing mechanisms of MGMT silencing may provide the basis for future clinical trials of novel therapies for melanoma and glioblastoma.

Acknowledgements

Firstly I would like to thank Associate Professor Kathryn Stowell for her excellent supervision for the duration of my studies. Your support, wisdom and tolerance have allowed me to learn from my mistakes and develop my skills inside and outside the laboratory.

Thank you to everyone in the Twilite Zone lab who kept me interested and made me want to come into the lab every day. I would especially like to thank Robyn Marsten for giving me guidance and for great cooking and gardening tips; Hilbert Grievink for your technical help and comradery; Amanda Gribble for your friendship and conversation; Lili Rhodes for your expert technical advice; Kei Sato for the invaluable Japanese lessons; Natisha Megan for your handy tips in the lab and finally Cornelia Roesl, Britta Majchrzak and Diana Balasubramanain for making the lab a friendlier place.

I am grateful to Alice Clark for help making figures, also for making my studies much more enjoyable. Thank you Nick Albert, Carlene Starck, Corey Laverty and John Tweedie for many enjoyable and insightful discussions. Thank you Cynthia Cresswell for help with Chemdraw. I would also like to thank Kelly Senior, Miranda Aalderink, Kate Silverwood and Julianne Neubert for their hard work on MGMT in our lab. I am grateful to those who donated the melanoma samples used in this study.

I would like to thank my family and friends for supporting me during my research and writing. Thank you Bev for always believing I could do it. Thank you George for always giving me the right advice when I need it most. Thank you Louise for your encouragement and help. Thank you Sharleen for always listening to my frustration with patience and my excitement with enthusiasm.

Lastly I would like to thank Massey University for helping finance my studies by way of a Masterate scholarship. I would like to thank IMBS for financial support which enabled me to travel to Queenstown to attend the epigenetics satellite meeting at the Queenstown molecular biology conference in 2008.

Table of contents

Abstract	i
Acknowledgements.....	ii
Table of contents.....	iii
List of figures	vii
List of tables	ix
Abbreviations	x
1 Introduction	1
1.1 Overview	1
1.2 Melanoma	2
1.2.1 Cancer and the cell	2
1.2.1.1 DNA-based events	3
1.2.1.2 Epigenetic changes in cancer.....	3
1.3 Anti cancer drugs	5
1.3.1 Temozolomide	6
1.4 O6-methyl-guanine methyltransferase (MGMT).....	8
1.4.1 MGMT expression and activity	8
1.5 Transcriptional machinery and MGMT promoter elements.....	9
1.5.1 5' cytosine DNA methylation of the MGMT promoter	11
1.6 Chromatin modifications	12
1.6.1 De Novo DNA methylation	14
1.6.2 Mechanisms for Methyl-CpG mediated silencing	15
1.7 Chromatin modifications and binding domains.....	17
1.7.1 Histone lysine acetylation.....	17
1.7.2 Histone methylation	18
1.7.2.1 Histone arginine methylation	19
1.7.2.2 Histone lysine methylation.....	19
1.7.2.3 H3K9 methylation.....	20
1.7.3 Histone serine phosphorylation.....	21
1.7.4 Chromatin remodelers and histone variants.....	21
1.7.5 A role for ncRNA?	22
1.7.6 Epigenetic events involved in MGMT transcription.....	23
1.8 Hypothesis and aims.....	24

2	Materials and methods	25
2.1	Materials	25
2.1.1	General chemicals	25
2.1.2	Equipment	25
2.1.3	Cell culture.....	25
2.1.3.1	Media and supplements.....	25
2.1.4	Antibodies	25
2.1.5	DNA manipulations.....	26
2.1.5.1	Restriction endonucleases and DNA modifying enzymes	26
2.1.5.2	PCR reagents	26
2.1.6	Chromatin manipulations.....	26
2.1.7	Software.....	26
2.2	Methods	27
2.2.1	Cell culture.....	27
2.2.1.1	Media preparation	27
2.2.1.2	Starting cells from frozen stock.....	27
2.2.1.3	Maintenance of cells	27
2.2.1.4	Preparing cells for freezing	28
2.2.2	DNA Manipulations	28
2.2.2.1	Phenol-chloroform extraction and ethanol precipitation.....	28
2.2.2.2	DNA quantification by absorbance at 260 nm or fluorescence.....	28
2.2.2.3	Block PCR.....	28
2.2.2.4	Agarose gel electrophoresis.....	29
2.2.2.5	Restriction endonuclease digestion.....	29
2.2.3	Methyl DNA immunoprecipitation	30
2.2.3.1	Genomic DNA extraction.....	30
2.2.3.2	DNA sonication	30
2.2.3.3	Immunoprecipitation.....	31
2.2.4	Chromatin immunoprecipitation (ChIP).....	31
2.2.4.1	Preparing cells for ChIP	31
2.2.4.2	Formaldehyde cross-linking	32
2.2.4.3	Chromatin sonication	32
2.2.4.4	Chromatin immunoprecipitation.....	32
3	Real-time quantitative PCR assay development.....	34

3.1	Introduction.....	34
3.2	MGMT promoter PCR	34
3.2.1	Amplification of the MGMT101 sequence by block PCR	37
3.2.2	Restriction endonuclease digestion of MGMT101 amplicon	39
3.3	Reference primer design and validation	40
3.3.1	β -actin primer design and Bact114 restriction endonuclease digestion	40
3.3.2	H19 primer design and H19155 restriction endonuclease digestion.....	42
3.4	Real time quantitative PCR	44
3.4.1	Amplification of target and reference sequences by RT quantitative PCR	46
3.5	PCR amplification efficiency determination	48
3.6	Chapter summary	50
4	Methyl DNA immunoprecipitation.....	51
4.1	Introduction.....	51
4.2	MeDIP optimisation	53
4.2.1	Isolation and sonication of genomic DNA	53
4.2.2	PCR-based control for sonication efficiency	54
4.2.2.1	Primer design.....	54
4.2.2.2	PCR amplification and restriction endonuclease digestion.....	55
4.2.2.3	Determination of sensitivity of sonication control	56
4.2.2.4	PCR to control for sonication efficiency.....	57
4.3	MeDIP results	58
4.3.1	Real time quantitative PCR and enrichment for NZM11 (1 of 3 replicates)	58
4.3.2	MeDIP results for seven cell lines.....	62
	Chapter summary	66
5	Chromatin immunoprecipitation.....	67
5.1	Introduction.....	67
5.2	Optimisation of the ChIP assay.....	68
5.2.1	Chromatin isolation, cross-linking and sonication.....	69
5.3	ChIP results.....	70
5.3.1	ChIP real time quantitative PCR and enrichment for NZM5 (1 of 3 replicates)	70
5.3.2	ChIP assay results for five cell lines	74
5.4	Chapter summary	77
6	Conclusions and future directions.....	78

6.1 Overview	78
Conclusions and discussion.....	79
6.1.1 MeDIP analysis	80
6.1.2 ChIP analysis.....	81
Summary	85
6.1.3 Possible sources of bias	86
6.1.3.1 Nucleosome reshuffling	86
6.1.3.2 Primer placement	86
6.2 Future directions	87
6.2.1 Future experiments.....	87
6.2.2 Clinical aspects.....	89
Bibliography	91
Appendices	101
Appendix I MGMT promoter sequence	101
Appendix II β -actin gene sequence.....	104
Appendix III H19 gene sequence.....	106
Appendix IV MeDIP plate setup for relative quantification	107
Appendix V MeDIP plate setup for standard curves	108
Appendix VI ChIP plate setup for absolute quantification	109
Appendix VII MeDIP data	110
Appendix IIX ChIP data.....	111

List of figures

Figure 1-1 The nucleosome core particle at 2.8 Angstrom resolution (Luger, et al., 1997).	4
Figure 1-2 Cytosine – Guanine base-pair. The additional 5' methyl group is depicted in red.	5
Figure 1-3 Physiological conversion of TMZ (left) to MTIC (right).	6
Figure 1-4 MTIC methyl lesions are depicted in red.	7
Figure 1-5 1157 bp fragment of the human MGMT promoter and potential regulatory elements (adapted from Harris et al., 1991).	9
Figure 1-6 Euchromatic and heterochromatic states and associated modifications. Adapted from (Allis, Jenuwein, & Reinberg, 2007).	13
Figure 1-7 Mechanisms for euchromatic gene silencing. Adapted from (Allis, et al., 2007)	16
Figure 1-8 Lysine and a selection of post-translational modifications	21
Figure 3-1 Schematic representation of restriction endonuclease cutting site and primer binding sites within a 675 bp MGMT promoter fragment of genomic DNA. Accession # NT_008818.16.	36
Figure 3-2 MGMT101 amplification by block PCR.	38
Figure 3-3 MGMT101 amplicon restriction endonuclease digest.	39
Figure 3-4 Schematic representation of restriction endonuclease cutting site and primer binding sites within a 675 bp β -actin gene fragment showing exons 2 and 3. Accession # NC_000007.13.	40
Figure 3-5 Bact114 amplicon restriction endonuclease digest.	41
Figure 3-6 Schematic representation of restriction endonuclease cutting site and primer binding sites within a 675 bp fragment within the H19 gene. Accession # NC_00001.9.	42
Figure 3-7 H19155 amplicon restriction endonuclease digest.	43
Figure 3-8 A) Amplification curves, B) melt curves and C) melt peaks of the MGMT101 amplicon.	45
Figure 3-9 Results of RT-qPCR for H19155, Bact114 and MGMT101 products.	47
Figure 3-10 Standard curve for the Bact114 amplicon for determination of PCR linearity. A) Amplification curves showing dilutions from stock. B) Corresponding melting peaks.	48

Figure 3-11 Standard curves for H19155, Bact114 and MGMT101 amplification reactions.	49
Figure 4-1 Genomic DNA isolated from melanoma cell lines and sonicated DNA respectively.....	53
Figure 4-2 Schematic representation of restriction endonuclease cutting site and primer binding sites within a 5863 bp fragment upstream of the MGMT gene. Accession NT_008818.16.....	54
Figure 4-3 MGMT1966 amplicon restriction endonuclease digestion with <i>Bam</i> HI.	55
Figure 4-4 PCR reactions on sonicated DNA spiked with serial dilutions of genomic DNA template.....	56
Figure 4-5 Template and PCR reactions using MGMT1966 primers for sonicated DNA prior to MeDIP procedure.	57
Figure 4-6 Amplification curves and enrichment for NZM11 β actin subset (replicate 1 of 3).....	59
Figure 4-7 Amplification curves and enrichment for NZM11 H19 subset (replicate 1 of 3).	60
Figure 4-8 MeDIP enrichment values and previously established MGMT expression values.	63
Figure 5-1 DNA purified from sonicated chromatin at 30 - 50 sonications.	69
Figure 5-2 Amplification curves and enrichment for NZM5, MGMT subset (1 of 3)... ..	71
Figure 5-3 Amplification curves and enrichment for NZM5, β actin subset (1 of 3).....	72
Figure 5-4 A) Relative enrichment of ChIP samples for the MGMT promoter and B) the β actin gene. Error bars shown are standard error. $n = 5$	75
Figure 6-1 Possible bias due to nucleosome reshuffling.....	86

List of tables

Table 2-1 Block PCR protocol for amplifying MGMT101 product.....	29
Table 3-1 Primers designed to amplify a 101 bp fragment upstream of exon 1.	35
Table 3-2 Block PCR protocol for amplifying MGMT101 product.....	37
Table 3-3 LC480 protocol for amplifying MGMT101, Bact114 and H19155 products	46
Table 6-1 Results summary for MeDIP data.....	80
Table 6-2 Results summary for MGMT ChIP data.	82
Table 6-3 Results summary for β actin ChIP data.....	83
Table 6-4 MGMT expression Cp's (M, Aalderink, personal communication, Nov, 2007)	84

Abbreviations

°C	degrees celsius
ADP	adenosine 5'-diphosphate
AGT	alkylguanine-transferase
AGAT	alkylguanine-alkyltransferase
AP1	activator protein 1
AP2	activator protein 2
ATP	adenosine 5'-triphosphate
ATF	activating transcription factor
α -MEM	alpha-minimal essential medium
bp	base pair
cAMP	cyclic adenosine 5'-monophosphate
CBP	cAMP response element binding protein
CHD	chromodomain helicase DNA-binding chromatin remodelling complex
ChIP	chromatin immunoprecipitation
Cp	crossing point
CpG	cytosine-guanine dinucleotide
CTD	carboxyl terminal domain
dNTP	2'-deoxynucleotide 5'-triphosphate
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
DNMT	DNA methyl-transferase
ds	double stranded
DSB	double stranded break
EDTA	ethylene-diamine-tetra-acetic acid
EJ	end joining
ES	embryonic stem cell
EtBr	ethidium bromide
FACT	facilitates chromatin transcription
FBS	foetal bovine serum
g	gram
gDNA	genomic DNA
GR	glucocorticoid receptor

GRE	glucocorticoid response element
H3K9	lysine 9 of histone H3
H3K9ac	acetylated lysine 9 of histone H3
H3K9me2	dimethylated lysine 9 of histone H3
H3K9me3	trimethylated lysine 9 of histone H3
HAT	histone acetyl transferase
HCl	hydrochloric acid
HDAC	histone deacetylase
HDACi	histone deacetylase inhibitor
HKMT	histone lysine methyl transferase
HP1	heterochromatin protein 1
HR	homologous recombination
INO80	inositol family chromatin remodelling complex
IP buffer	immunoprecipitation buffer
ISWI	imitation switch family chromatin remodelling complex
ITS	insulin-transferrin selenite
JmjC	jumanji-C domain
kb	kilobase-pairs
L	litre
LC480	lightcycler 480 instrument
LSD	lysine demethylase
M	moles per litre
MAF	masculoaponeurotic fibrosarcoma
MBD	methyl binding domain
MeCP2	methyl CpG binding protein 2
MeDIP	methyl-DNA immunoprecipitation
MGMT	O6 methyl-guanine DNA-methyltransferase
µg	microgram
µL	micolitre
µM	micro moles per litre
mg	milligram
mL	millilitre
MML	mixed lineage leukemia
mM	milli moles per litre

MMR	mismatch repair
M_r	relative molecular mass (g mol^{-1})
mRNA	messenger ribonucleic acid
MTIC	5-(3-methyltriazene-1-yl)imidazole-4-carboxamide
NaOAc	sodium acetate
ncRNA	non-coding RNA
NDR	nucleosome depleted region
Nmol	nanomole
Nt	nucleotide
NZM	New Zealand melanoma
$\text{O}^6\text{-MG}$	guanine nucleotide with methylation of the O^6 position
OGAT	O^6 -alkylguanine transferase
PBS	phosphate buffered saline
PcG	polycomb group
PCR	polymerase chain reaction
pH	$-\text{Log} [\text{H}^+]$
PKC	protein kinase C
PRMT	protein arginine methyltransferase
RB	retinoblastoma protein
RISC	RNA-induced silencing complex
RITS	RNA-induced transcriptional silencing
RNA	ribonucleic acid
RNApolII	RNA polymerase II
RNApolIIo	elongation competent RNApolII
RNase	ribonuclease
RNAi	RNA interference
ROS	reactive oxygen species
rpm	revolutions per minute
RT	room temperature
RT-qPCR	real time-quantitative polymerase chain reaction
s	second
SAM	s-adenosyl methionine
SDS	sodium dodecyl sulphate
siRNA	short interfering RNA

SWI/SNF	mating type switching/sucrose non-fermenting family
TAE	tris-HCl, acetic acid, EDTA buffer
TBP	TATA binding protein
TE	tris-HCl, EDTA buffer
TF	transcription factor
TMZ	temozolomide
Tris	tris(hydroxymethyl)aminomethane
TrypleE	express stable trypsin-like enzyme plus phenol red
TSP	transcription start point
UV	ultraviolet light
V	volt ($\text{m}^2 \text{ kg s}^{-3} \text{ A}^{-1}$)